Time filter

Source Type


Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: NMP.2011.1.4-4 | Award Amount: 5.24M | Year: 2012

The main goal of this proposal is to bring novel technology of biocompatible, low bio-fouling, high electrochemical performance carbon nanomaterials to in-vivo preclinical applications and at the same time to use this materials to develop a highly advanced concept of intimate intracellular contact, based on bottom - up technology of, engulfing the micro-electrode by neural cells. Such bionic interfaces resemble true intrinsic physiological properties of neural somas and form a tight, extremely low-invasive bidirectional coupling for both motor and sensory functions. Advantage of our approach is unperfected fidelity of signals and resolution of single neuron fibers to be coupled to one protruding electrode. The research targets are devices ranging from cuff or lead electrodes to novel bidirectional interfaces for both sensory and motor functions for cybernetic mind-controlled prosthetics. Instead of re-targeting to an entire muscle, our research comes thus with a technique how to couple neurons by an intracellular way to form a single microelectrode-axon stimulating device and at the same time to provide sensory input , being on the front edge of research on bionic interfaces for novel neuroprosthetics. The proposed technology takes advantage of unique properties of well established nanodiamond thin films, with their unique and the simple carbon chemistry allowing integration with antibactericidal and anti-inflammatory surfaces. MERIDIAN will demonstrate devices in in-vivo studies and in preclinical tests on humans and benchmark fabricated devices with the current state of the art bionic system on the market.

Agency: Cordis | Branch: H2020 | Program: IA | Phase: ICT-24-2015 | Award Amount: 3.84M | Year: 2016

INPUT will strive to make the control of complex upper limb prostheses simple, natural and to be used on a daily basis by amputees effortlessly after donning -don and play. Currently, the most advanced routine prosthetic control on the market is more than 4 decades old, outdated and constitutes the bottle neck to introducing highly dexterous prostheses. The project builds on achievements reached in the EU FP7 IAPP projects AMYO (Grant No. 251555, 2011-2014) and MYOSENS (Grant No. 286208, 2012-2015), which were targeting improved signal acquisition and signal processing for advanced upper limb prosthetic control. The projects were very successful and received high recognitions national and international recognitions. In INPUT, the main goal will be to transfer the obtained results from laboratory settings further towards a clinically and commercially viable medical product. The enabling concepts on which INPUT builds upon are: - Reliable, easy to apply, cost-effective signal acquisition - Reliable, powerful real-time signal processing - Quantifying true patient benefit - Optimized end-user training - Iterative clinical tests throughout the entire project In order to keep a realistic focus, the project will rely on well-known principles of advanced prosthesis control. Existing upper limb prosthetic hardware will be reused to minimize development time and costs. Improved electronics, algorithms and training will be the main innovations. INPUT will build on frequent end-user testing with amputees throughout the entire project. These will ensure targeted prototype development and market viability for advancing the technology from laboratory conditions to a high technology readiness level (TRL) of 8. The project relies on the cooperation between academic research, industry and clinical partners - thus representing the entire value chain of cutting edge upper limb prosthetics. This will ensure the development of stable, wearable and practical prototypes.

Agency: Cordis | Branch: FP7 | Program: MC-IAPP | Phase: FP7-PEOPLE-2011-IAPP | Award Amount: 1.73M | Year: 2012

Biological signals recorded from the human body can be translated into actions of external devices to create man-machine interaction. This concept has clinical implications in rehabilitation technologies for replacing or recovering impaired motor functions. Among the possible biosignals for man-machine interaction (brain, nerve, and muscle signals), muscle signals, i.e. electromyography (EMG), are the only that allow applications in routine clinical use within a commercially reasonable time horizon. Although the current efforts in myoelectric interfaces are mainly focusing on decoding EMG signals, myoelectric interaction has the unique and little exploited feature of provoking changes in the neural circuits that are active during the interaction, i.e. of artificially inducing brain plasticity. However, current commercially viable myoelecric interfaces do not implement sensory-motor integration (decoding intentions and at the same time providing a sensory feedback to the patient), which conversely is the basis of plasticity of the central nervous system. This limit reflects the gap between academic research and the clinical and commercial needs. Myoelectric interfacing with sensory-motor integration is indeed feasible now if the knowledge from basic neurophysiology research and signal analysis in the academia is transferred to industrial sectors and if the requirements of and testing for clinical and commercial viability are transferred from the industry to academia. With a consortium of internationally regarded European academic teams and industries, we thus propose the implementation of sensory-motor integration into commercially viable myoelectric devices in two key clinical applications: 1) training for the active control of prostheses; and 2) rehabilitation of stroke patients with robotics. These two areas require a similar technological ground for sensory-motor integration and for artificial induction of neural plasticity, necessary to (re)learn motor tasks.

Otto Bock Healthcare Gmbh | Date: 2016-03-29

Chemicals used in industry; unprocessed artificial resins; unprocessed plastics, in particular unprocessed thermoplastics in form of powder, liquids and granulates; adhesives used in industry. Orthopedic articles; orthopedic bandages; artificial limbs and their parts. Plastics in extruded form for use in manufacture, in particular thermoplastics as semi-finished products in form of blocks, rods or boards; artificial resins and synthetic resins (semi-finished); semi-finished synthetic materials and resins in form of tapes; packing, stopping and insulating materials; padding materials (stuffing material).

Otto Bock Healthcare Gmbh | Date: 2016-02-01

Orthopedic and mobility aids; orthoses; orthopedic bandages; parts and fittings of all the aforesaid goods, included in this class. Retail and wholesale services in relation to orthopedic articles.

Discover hidden collaborations